Patent details
EP3402486 Title: CCX168 FOR USE IN THE TREATMENT OF C3 GLOMERULOPATHY
Basic Information
- Publication number:
- EP3402486
- PCT Application Number:
- US2017013132
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP177389020
- PCT Publication Number:
- WO2017123716
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- CCX168 FOR USE IN THE TREATMENT OF C3 GLOMERULOPATHY
- French Title of Invention:
- CCX168 POUR SON UTILISATION DANS LE TRAITEMENT D'UNE GLOMÉRULOPATHIE À C3
- German Title of Invention:
- CCX168 ZUR VERWENDUNG BEI DER BEHANDLUNG VON C3-GLOMERULOPATHIE
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 11/04/2025
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 22/04/2025
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 19/03/2025
- Unitary Effect Registration Date:
- 22/04/2025
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 12/01/2017
- Grant date:
- 19/03/2025
- EP Publication Date:
- 21/11/2018
- PCT Publication Date:
- 20/07/2017
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 19/03/2025
- EP B1 Publication Date:
- 19/03/2025
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 12/01/2037
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 08/05/2025
- Name:
- ChemoCentryx, Inc.
- Address:
- One Amgen Center Drive, Thousand Oaks, CA 91320, United States (US)
History of Owners
- From:
- 12/03/2025
- To:
- 08/05/2025
- Name:
- ChemoCentryx, Inc.
- Address:
- 850 Maude Avenue, Mountain View, California 94043, United States (US)
Inventor
- Name:
- BEKKER, Petrus
- Address:
- United States (US)
Priority
1
- Priority Number:
- 201662278788 P
- Priority Date:
- 14/01/2016
- Priority Country:
- United States (US)
2
- Priority Number:
- 201662280346 P
- Priority Date:
- 19/01/2016
- Priority Country:
- United States (US)
3
- Priority Number:
- 201662347450 P
- Priority Date:
- 08/06/2016
- Priority Country:
- United States (US)
4
- Priority Number:
- 201662397527 P
- Priority Date:
- 21/09/2016
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 31/551; A61P 13/12; A61K 31/454;
Publication
European Patent Bulletin
1
- Issue number:
- 202512
- Publication date:
- 19/03/2025
- Description:
- Grant (B1)
2
- Issue number:
- 202524
- Publication date:
- 11/06/2025
- Description:
- Change of owner's name or address
3
- Issue number:
- 202521
- Publication date:
- 21/05/2025
- Description:
- Unitary Effect Request Receipt
4
- Issue number:
- 202521
- Publication date:
- 21/05/2025
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|